Liminatus Pharma, Inc. Class A Common Stock (NASDAQ:LIMN) — Market Cap & Net Worth
Market Cap & Net Worth: Liminatus Pharma, Inc. Class A Common Stock (LIMN)
Liminatus Pharma, Inc. Class A Common Stock (NASDAQ:LIMN) has a market capitalization of $5.33 Million ($5.33 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #28233 globally and #5565 in its home market, demonstrating a 2.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Liminatus Pharma, Inc. Class A Common Stock's stock price $0.21 by its total outstanding shares 26014600 (26.01 Million). Analyse Liminatus Pharma, Inc. Class A Common St (LIMN) cash flow conversion to see how efficiently the company converts income to cash.
Liminatus Pharma, Inc. Class A Common Stock Market Cap History: 2025 to 2026
Liminatus Pharma, Inc. Class A Common Stock's market capitalization history from 2025 to 2026. Data shows growth from $15.87 Million to $5.33 Million (0.00% CAGR).
Liminatus Pharma, Inc. Class A Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Liminatus Pharma, Inc. Class A Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LIMN by Market Capitalization
Companies near Liminatus Pharma, Inc. Class A Common Stock in the global market cap rankings as of May 4, 2026.
Key companies related to Liminatus Pharma, Inc. Class A Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Liminatus Pharma, Inc. Class A Common Stock Historical Marketcap From 2025 to 2026
Between 2025 and today, Liminatus Pharma, Inc. Class A Common Stock's market cap moved from $15.87 Million to $ 5.33 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $5.33 Million | -66.39% |
| 2025 | $15.87 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Liminatus Pharma, Inc. Class A Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.33 Million USD |
| MoneyControl | $5.33 Million USD |
| MarketWatch | $5.33 Million USD |
| marketcap.company | $5.33 Million USD |
| Reuters | $5.33 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 201… Read more